You are here

The Progress Report Progress never stops. Stay informed with the latest news on breast cancer research, treatment, and prevention.

Tag:

BRCA2 x

Soon after Arnaldo Silva discovered the suspicious lump on his chest was breast cancer, he also learned he was a BRCA2 mutation carrier. He was devastated and shocked but hopeful it could help his two children understand their cancer risk. It did more than that.

Identifying high-risk individuals is key to preventing breast cancer

Mutations, or alterations, in the “cancer-fighting” genes BRCA1 or BRCA2, can dramatically increase person’s risk of breast cancer. Women with a mutation in BRCA1/2 have a 6-7 times greater risk of developing breast cancer and men with the mutation have an over 80 times greater risk.

The discovery of the BRCA1 and BRCA2 genes more than 20 years ago dramatically changed risk assessment, prevention and treatment in families with a high prevalence of breast and/or ovarian cancers.

PARP inhibitors are drugs that target tumors with BRCA1/BRCA2 mutated cells and the first PARP inhibitor was approved in 2015 as a targeted therapy for ovarian cancer patients with BRCA1/2 mutations.

BCRF grantee Dr. Susan Domchek spoke to us about a  new study she co-authored on genetic testing for breast cancer in the “New England Journal of Medicine.” Dr. Domchek explains:

You asked, we listened and the answers are in.

Our #AskBCRF social media event was tailored for those who have been diagnosed with breast cancer – their siblings, children and relatives – who had questions surrounding inherited susceptibility to breast and ovarian cancer.

After actress and filmmaker Angelina Jolie Pitt revealed she underwent two preventive surgeries to remove her ovaries, fallopian tubes, and both breasts because she carries a B

Each year, we invite our grantees to New York for our October Symposium and Awards Luncheon. Before taking the stage, our researchers take part in a scientific meeting, a tradition that’s been in place since 2003.

While breast cancers are known to run in families, they are rarely a direct result of mutated genes inherited from a parent. In fact, inherited, or hereditary, cases account for only 5 - 10 percent of all breast cancers.